Data on Measles Detailed by K.M. Thompson and Co-Authors (Modeling the Transmission of Measles and Rubella to Support Global Management Policy…

Vaccine Weekly

Data on Measles Detailed by K.M. Thompson and Co-Authors (Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases)

By a News Reporter-Staff News Editor at Vaccine Weekly -- Fresh data on Infectious Diseases and Conditions - Measles are presented in a new report. According to news reporting out of Orlando, Florida, by NewsRx editors, research stated, "Policy makers responsible for managing measles and rubella immunization programs currently use a wide range of different vaccines formulations and immunization schedules. With endemic measles and rubella transmission interrupted in the region of the Americas, all five other regions of the World Health Organization (WHO) targeting the elimination of measles transmission by 2020, and increasing adoption of rubella vaccine globally, integrated dynamic disease, risk, decision, and economic models can help national, regional, and global health leaders manage measles and rubella population immunity."

Financial support for this research came from Alliance for Health Policy and Systems Research (see also Infectious Diseases and Conditions - Measles).

Our news journalists obtained a quote from the research, "Despite hundreds of publications describing models for measles or rubella and decades of use of vaccines that contain both antigens (e.g., measles, mumps, and rubella vaccine or MMR), no transmission models for measles and rubella exist to support global policy analyses. We describe the development of a dynamic disease model for measles and rubella transmission, which we apply to 180 WHO member states and three other areas (Puerto Rico, Hong Kong, and Macao) representing >99.5% of the global population in 2013. The model accounts for seasonality, age-heterogeneous mixing, and the potential existence of preferentially mixing undervaccinated subpopulations, which create heterogeneity in immunization coverage that impacts transmission. Using our transmission model with the best available information about routine, supplemental, and outbreak response immunization, we characterize the complex transmission dynamics for measles and rubella historically to compare the results with available incidence and serological data. We show the results from several countries that represent diverse epidemiological situations to demonstrate the performance of the model. The model suggests relatively high measles and rubella control costs of approximately $3 billion annually for vaccination based on 2013 estimates, but still leads to approximately 17 million disability-adjusted life years lost with associated costs for treatment, home care, and productivity loss costs of approximately $4, $3, and $47 billion annually, respectively. Combined with vaccination and other financial cost estimates, our estimates imply that the eradication of measles and rubella could save at least $10 billion per year, even without considering the benefits of preventing lost productivity and potential savings from reductions in vaccination. The model should provide a useful tool for exploring the health and economic outcomes of prospective opportunities to manage measles and rubella."

According to the news editors, the research concluded: "Improving the quality of data available to support decision making and modeling should represent a priority as countries work toward measles and rubella goals."

For more information on this research see: Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases. Risk Analysis, 2017;():. (Wiley-Blackwell - www.wiley.com/; Risk Analysis - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1539-6924)

Our news journalists report that additional information may be obtained by contacting K.M. Thompson, Kid Risk Inc, Orlando, FL, United States.

Keywords for this news article include: Orlando, Florida, Rubella, Vaccines, RNA Viruses, Vaccination, Epidemiology, Immunization, United States, German Measles, Biological Products, Public Health Practice, Morbillivirus Infections, North and Central America, World Health Organization, Paramyxoviridae Infections, Communicable Disease Control.